Pfizer Amends 13D Filing on Longboard Pharmaceuticals Stake

TL;DR

**Pfizer updated its stake in Longboard, signaling continued oversight.**

AI Summary

Pfizer Inc. filed an Amendment No. 3 to its Schedule 13D on January 25, 2024, regarding its ownership in Longboard Pharmaceuticals, Inc. This filing updates previous disclosures about Pfizer's stake in Longboard's Common Stock, par value $0.0001 per share. This matters to investors because it provides transparency into a major pharmaceutical company's continued involvement and influence over a smaller, specialized drug developer, which could signal future strategic moves or divestitures.

Why It Matters

This filing indicates Pfizer's ongoing reporting obligations and potential strategic interest in Longboard Pharmaceuticals, which could impact Longboard's stock valuation and future direction.

Risk Assessment

Risk Level: low — This is an informational update filing and does not inherently present new risks, but rather clarifies existing ownership structures.

Analyst Insight

Investors should note Pfizer's continued reporting on its Longboard stake, but this specific filing is purely administrative. Further amendments or other filings would be needed to infer any new strategic actions.

Key Players & Entities

• Pfizer Inc. (company) — the filing person and reporting entity
• Longboard Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported
• Margaret M. Madden, Esq. (person) — Senior Vice President and Corporate Secretary, Chief Governance Counsel for Pfizer Inc.
• DLA Piper LLP (US) (company) — legal counsel for Pfizer Inc.
• $0.0001 (dollar_amount) — par value per share of Longboard Pharmaceuticals' Common Stock

FAQ

From the Filing

0000078003-24-000015.txt : 20240129 0000078003-24-000015.hdr.sgml : 20240129 20240129170105 ACCESSION NUMBER: 0000078003-24-000015 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 GROUP MEMBERS: ARENA PHARMACEUTICALS, INC. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Longboard Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001832168 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 845009619 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92379 FILM NUMBER: 24574490 BUSINESS ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 950 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 619-592-9775 MAIL ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 950 CITY: LA JOLLA STATE: CA ZIP: 92037 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 SC 13D/A 1 sch13dalongboard124x.htm SC 13D/A LONGBOARD PHARMACEUTICALS Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc. 66 Hudson Boulevard East New York, New York 10001 (212) 733-2323 Copy to: DLA Piper LLP (US) 650 South Exeter Street, Suite 1100 Baltimore, MD 21202 (410) 580-3000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 25, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP NO: 54300N103 Page 2 of 5 1. NAMES OF REPORTING PERSONS Pfizer Inc. (“Pfizer”) 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b)  ☐ 3. SEC USE ONLY 4. SOURCE OF FUNDS OO 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6. CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 0 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 0 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY E